Please login to the form below

Not currently logged in
Email:
Password:

Zontivity

This page shows the latest Zontivity news and features for those working in and with pharma, biotech and healthcare.

FDA reviewer backs approval of TMC's cangrelor

FDA reviewer backs approval of TMC's cangrelor

Additional competition in the category will also come from Merck &Co's first-in-class protease-activated receptor-1 (PAR-1) antagonist Zontivity (vorapaxar) - which was cleared for marketing in the

Latest news

  • R&D productivity takes off R&D productivity takes off

    Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a

  • Orphan drugs in latest CHMP recommendations Orphan drugs in latest CHMP recommendations

    s Zontivity (vorapaxar), which was recommended for the reduction of atherothrombotic events.

  • Merck's first-in-class Zontivity cleared in US Merck's first-in-class Zontivity cleared in US

    Merck's first-in-class Zontivity cleared in US. FDA approves the protease-activated receptor-1 antagonist to reduce heart attack risk. ... Merck plans to launch Zontivity in the US in the coming weeks, while the PAR-1 antagonist is also under regulatory

  • FDA panel backs Merck's vorapaxar FDA panel backs Merck's vorapaxar

    Vorapaxar - which Merck plans to sell under the brand name Zontivity - is an orally-active protease-activated receptor 1 (PAR-1) inhibitor that targets thrombin-induced platelet activation. ... If the FDA follows the panel's advice - which it generally

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Merck &Co has sold the US and Canadian rights for its Zontivity, or vorapaxar, to Aralez Pharmaceuticals in an asset purchase agreement worth $25m. ... Zontivity is a protease-activated receptor-1 antagonist indicated for use in combination with daily

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics